D59.39

Other hemolytic-uremic syndrome

Risk-adjusting (HCC)Billable code

HCC risk adjustment mapping

CMS-HCC V28

HCC109

Acquired Hemolytic, Aplastic, and Sideroblastic Anemias

CMS-HCC ESRD V24

HCC46

Severe Hematological Disorders

RxHCC V08

RXHCC96

Acquired Hemolytic, Aplastic, and Sideroblastic Anemias

Coding notes

Excludes 1 never coded together · Excludes 2 may co-exist

This code · D59.39
Use additional

code, if applicable, for adverse effect to identify drug (T36-T50 with fifth or sixth character 5)

Code first

, if applicable, any associated: COVID-19 (U07.1) complications of kidney transplant (T86.1-) complications of heart transplant (T86.2-) complications of liver transplant (T86.4-)

Code also

, if applicable, any associated condition, such as: hypertensive emergency (I16.1) malignant neoplasm (C00-C96) systemic lupus erythematosus (M32.-)

Synonyms

Atypical (nongenetic) hemolytic uremic syndrome Secondary hemolytic-uremic syndrome

Inherited from D59.3Hemolytic-uremic syndrome
Code also

, if applicable, any associated: acute kidney failure (N17.-) chronic kidney disease (N18.-)

Inherited from chapter 3Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
Excludes 2

autoimmune disease (systemic) NOS (M35.9) certain conditions originating in the perinatal period (P00-P96) complications of pregnancy, childbirth and the puerperium (O00-O9A) congenital malformations, deformations and chromosomal abnormalities (Q00-Q99) endocrine, nutritional and metabolic diseases (E00-E88) human immunodeficiency virus [HIV] disease (B20) injury, poisoning and certain other consequences of external causes (S00-T88) neoplasms (C00-D49) symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)

Official Guidelines for D59.39

FY 2026 ›